In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
Avidity Biosciences Inc (NASDAQ: RNA) closed the day trading at $31.72 up 4.07% from the previous closing price of $30.48. In other words, the price has increased by $4.07 from its previous closing price. On the day, 1.17 million shares were traded. RNA stock price reached its highest trading level at $31.88 during the session, while it also had its lowest trading level at $30.33.
Ratios:
For a better understanding of RNA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.73 and its Current Ratio is at 15.73. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on March 13, 2025, initiated with a Buy rating and assigned the stock a target price of $70.
On March 12, 2025, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $72.
On March 07, 2025, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $70.Scotiabank initiated its Sector Outperform rating on March 07, 2025, with a $70 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 11 ’25 when Flanagan W. Michael sold 20,000 shares for $30.13 per share. The transaction valued at 602,614 led to the insider holds 91,975 shares of the business.
WILLIAM MICHAEL FLANAGAN bought 20,000 shares of RNA for $600,800 on Mar 11 ’25. On Mar 03 ’25, another insider, Gallagher Kathleen P., who serves as the Chief Program Officer of the company, sold 5,875 shares for $29.41 each. As a result, the insider received 172,807 and left with 50,554 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 3813124608 and an Enterprise Value of 2318438144. For the stock, the TTM Price-to-Sale (P/S) ratio is 349.83 while its Price-to-Book (P/B) ratio in mrq is 2.67. Its current Enterprise Value per Revenue stands at 212.759 whereas that against EBITDA is -6.163.
Stock Price History:
The Beta on a monthly basis for RNA is 0.99, which has changed by 0.3161826 over the last 52 weeks, in comparison to a change of 0.08275449 over the same period for the S&P500. Over the past 52 weeks, RNA has reached a high of $56.00, while it has fallen to a 52-week low of $21.56. The 50-Day Moving Average of the stock is 2.05%, while the 200-Day Moving Average is calculated to be -18.23%.
Shares Statistics:
Over the past 3-months, RNA traded about 1.35M shares per day on average, while over the past 10 days, RNA traded about 1263020 shares per day. A total of 119.89M shares are outstanding, with a floating share count of 111.07M. Insiders hold about 7.61% of the company’s shares, while institutions hold 103.98% stake in the company. Shares short for RNA as of 1740700800 were 16954734 with a Short Ratio of 12.56, compared to 1738281600 on 14949939. Therefore, it implies a Short% of Shares Outstanding of 16954734 and a Short% of Float of 17.36.
